CIZZLE BIOTECHNOLOGY HOLDINGS PLC Cizzle Biotechnology Holdings Plc Share Price
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.73 GBX | +3.28% |
|
+3.28% | -11.28% |
| 04-30 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| 04-30 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 7.09M 9.03M 709M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | -1M -1.27M -100M | EV / Sales 2022 | - |
| Net cash position 2022 | 478K 609K 47.8M | Net cash position 2023 | 1.56M 1.98M 156M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.63
x | P/E ratio 2023 |
-4.04
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.88% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.28% | ||
| 1 week | +3.28% | ||
| Current month | +4.85% | ||
| 1 month | +1.76% | ||
| 3 months | -24.78% | ||
| 6 months | -15.61% | ||
| Current year | -11.28% |
1 week
1.60
1.80
1 month
1.571.85
Current year
1.573.38
1 year
1.573.38
3 years
1.308.25
5 years
1.3013.00
10 years
1.3013.00
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lee
DFI | Director of Finance/CFO | 63 | 13/05/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dawn Coverley
BRD | Director/Board Member | 59 | 13/05/21 |
Nigel Lee
DFI | Director of Finance/CFO | 63 | 13/05/21 |
John Treacy
BRD | Director/Board Member | 42 | 28/01/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/05/24 | 1.73 | +3.28% | 428 815 |
| 22/05/24 | 1.675 | 0.00% | 222,236 |
| 21/05/24 | 1.675 | 0.00% | 87,584 |
| 20/05/24 | 1.675 | 0.00% | 153,570 |
| 17/05/24 | 1.675 | 0.00% | 473,742 |
Delayed Quote London S.E., May 23, 2024 at 11:28 am
More quotes
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Calendar
15/05/2025
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.28% | 8.45M | |
| +64.23% | 62.59B | |
| -2.31% | 41.18B | |
| +44.81% | 40.29B | |
| -8.29% | 27.9B | |
| +11.97% | 26.21B | |
| -21.16% | 19.09B | |
| +7.54% | 13.08B | |
| +25.72% | 12.26B | |
| +27.17% | 12.05B |
- Stock Market
- Equities
- PSL Stock
